The incidence and mortality of lung cancer are generally high,which severely threatens the public health.Surgery remains an excellent intervention strategy for resectable non-small cell lung cancer(NSCLC).The emergence of immune checkpoint inhibitors has greatly changed the intervention effectiveness of NSCLC.As demonstrated by in-depth studies,immune checkpoint inhibitors exhibit high safety and feasibility in the treatment of NSCLC.However,there is still a lack of long-term evaluation of these drugs and consensus on the treatment regimens and the course of treatment.This review will elucidate the development,mechanism and research status of the neoadjuvant immunotherapy for resectable NSCLC.
维普
万方数据